ArrowMark Colorado Holdings LLC Has $1.60 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

ArrowMark Colorado Holdings LLC lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 21.7% during the third quarter, Holdings Channel reports. The fund owned 12,300 shares of the life sciences company’s stock after selling 3,400 shares during the quarter. ArrowMark Colorado Holdings LLC’s holdings in Illumina were worth $1,604,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Comerica Bank grew its stake in shares of Illumina by 22.2% in the 1st quarter. Comerica Bank now owns 32,070 shares of the life sciences company’s stock valued at $4,404,000 after buying an additional 5,819 shares during the period. Virtu Financial LLC acquired a new stake in Illumina in the first quarter valued at approximately $271,000. Cetera Investment Advisers increased its holdings in shares of Illumina by 361.1% during the first quarter. Cetera Investment Advisers now owns 14,617 shares of the life sciences company’s stock valued at $2,007,000 after acquiring an additional 11,447 shares in the last quarter. Cetera Advisors LLC bought a new stake in shares of Illumina during the first quarter valued at approximately $610,000. Finally, DNB Asset Management AS lifted its holdings in shares of Illumina by 10.9% in the 2nd quarter. DNB Asset Management AS now owns 27,164 shares of the life sciences company’s stock worth $2,835,000 after purchasing an additional 2,679 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on ILMN. StockNews.com began coverage on shares of Illumina in a report on Thursday, August 29th. They set a “buy” rating on the stock. Daiwa America upgraded shares of Illumina to a “strong-buy” rating in a report on Friday, August 16th. Scotiabank cut their price target on Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research note on Thursday, August 15th. Piper Sandler lowered their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Finally, Barclays raised their target price on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $164.00.

Illumina Trading Up 0.7 %

NASDAQ:ILMN opened at $145.15 on Tuesday. Illumina, Inc. has a 12 month low of $100.08 and a 12 month high of $156.66. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The firm’s 50 day moving average is $141.88 and its 200 day moving average is $126.03.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the previous year, the company posted $0.33 earnings per share. The business’s revenue was down 3.5% on a year-over-year basis. Equities research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.